The federal TrumpRx website lists Johnson & Johnson’s blood thinner Xarelto starting at $197, against an original price of $611.82. Orders are not filled by TrumpRx itself. The listing’s button reads “Get started with J&J Direct,” the manufacturer’s own direct-to-patient program, which ships the medicine and sets who qualifies.
What the TrumpRx listing shows for Xarelto
On the Xarelto page at TrumpRx.gov, the headline price reads “Starting at $197.00” and the original price is $611.82. The site marks the difference as a $414.82 saving, or 68% off. The drug is listed as a tablet made by Johnson & Johnson in 10, 15 and 20 milligram strengths, in quantities of 30 or 90. The same price appears on the site’s presidential deals listing, which shows the same $197.00 against the same $611.82.
The page carries a plain limit: “This is an out-of-pocket price.” Patients with insurance are told to check their co-pay first, because it “may be even lower.” That sentence is the one that matters for patients who fill Xarelto through a Part D drug plan. For them the question is which number is lower for the same strength and count: the plan’s copay or the cash price.
TrumpRx itself says an insurance co-pay “may be even lower” than the $197 cash price. The Medicare Cost & Coverage Protection Kit lays out the new Part D out-of-pocket cap and 51 state Medicare cost-help packs, which are the two figures that decide whether a plan or a cash price wins.
Weigh the $197 Xarelto cash price against Part D with the Cost & Coverage Protection Kit →
How J&J Direct fills the order
TrumpRx hands the sale to Johnson & Johnson Innovative Medicine. On the J&J Direct page, the company lists Xarelto at $197.00 for a 30-count bottle and $591.00 for a 90-count bottle. The two prices work out to the same cost per tablet, about $6.57. A larger bottle therefore lowers the number of orders, not the price of each pill.
J&J describes the program as delivering prescribed medicines to eligible patients who are uninsured or who face coverage and affordability gaps. The TrumpRx page leaves eligibility and terms to J&J Direct, which walks users through them after the click. For anyone with a Part D plan that covers Xarelto, whether J&J Direct will take the order is a question for J&J. TrumpRx’s Xarelto page says nothing about Medicare. Questions about the program can go to the support line on the TrumpRx page, 1-855-522-3241, open 9 a.m. to 9 p.m. Eastern, Monday through Friday.
In practice the TrumpRx page works as a front door. The price a patient sees there is the one J&J publishes on its own program page, and the order, the shipping and the eligibility review all happen on J&J’s side. J&J’s page carrying those prices is dated March 26, 2026, and the TrumpRx listing repeats it.
A cash price set beside a Part D plan
The question for a Medicare patient on this drug is a comparison, and it has three parts: the monthly copay on the plan’s formulary, the annual out-of-pocket limit on Part D spending, and the cash price. Medicare.gov says the Part D out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027, after which a plan member moves into catastrophic coverage. Medicare counts a member’s spending on covered Part D drugs toward that limit, including certain payments made on the member’s behalf, such as through the Extra Help program. The page also says State Pharmaceutical Assistance Program contributions may count.
A cash purchase made outside the plan is a different track, and the TrumpRx page flags the $197 as a price paid without insurance. A patient who buys that way is paying for the drug directly, not running it through the plan’s deductible, copay or yearly limit.
What the price does not say
TrumpRx’s figure is a starting price, and the page does not say which strength or count the $197.00 applies to. J&J’s own page ties $197.00 to a 30-count bottle, so a patient on a different strength or a 90-count supply should expect to read the final price at checkout, not on the listing. The original price of $611.82 is TrumpRx’s reference figure for the default configuration. It is not a copay and not what an insurer pays.
The savings percentage is arithmetic on that reference figure: $414.82 off $611.82 is 68%. A patient whose plan charges a flat copay for the drug may owe less than either number, and a patient still in a deductible phase may owe more.
Comparing a $197 cash price with a plan copay
The first free check is the plan’s own price for Xarelto: the member’s Part D or Medicare Advantage drug plan can quote the copay for the exact strength and quantity, and the pharmacy that fills it can confirm. That figure goes next to the cash price on TrumpRx.gov for the same strength and count.
Three details to gather: the strength in milligrams, the quantity per fill, and how much has been spent on covered drugs so far this year. Patients on a limited income should also look at state and federal drug help, because Medicare.gov says people with Medicaid, a Medicare Savings Program or SSI automatically qualify for Extra Help.
The prices themselves are J&J’s and the federal site’s to change. Both TrumpRx and J&J Direct state the $197 figure today, and J&J’s page was last dated March 2026.
Xarelto’s $197 cash price versus a plan copay
A patient who picks the cash price without checking the plan copay can pay more than needed, and one who ignores state help can miss a program that covers part of the bill. The Medicare Cost & Coverage Protection Kit includes 51 state Medicare cost-help packs and explains the new Part D out-of-pocket cap, so the comparison starts from the patient’s own state and plan. It is a 15-page guide.
Find your state’s Medicare cost-help pack in the Cost & Coverage Protection Kit →
This article was produced with AI assistance and reviewed by The Financial Wire’s editorial team.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
